Cantor Fitzgerald analyst Olivia Brayer raised the firm’s price target on Verona Pharma (VRNA) to $100 from $90 and keeps an Overweight rating on the shares. There is plenty more upside to the story as long as there’s a clear path to Ohtuvayre becoming a $4B+ peak franchise, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRNA:
- Verona Pharma price target raised to $110 from $95 at Jefferies
- Verona Pharma management to meet with Piper Sandler
- Verona Pharma’s Ohtuvayre Positioned for Market Dominance Amid Reduced Competition
- Verona Pharma price target raised to $90 from $85 at H.C. Wainwright
- Verona Pharma price target raised to $107 from $93 at Wells Fargo